Vitals Knowledge Vault

Melatonin — Mechanism

5 min read

Melatonin — Mechanism

TL;DR

Melatonin acts through two G-protein-coupled receptors — MT1 (promotes sleep propensity) and MT2 (shifts circadian phase) — to signal darkness to the suprachiasmatic nucleus (SCN). Its effects on sleep are downstream of this timing signal. The phase response curve (PRC) determines timing sensitivity: taken in the early evening, melatonin advances the clock; taken at bedtime, it falls in a “dead zone.” HPA axis modulation is present but modest and context-dependent at supplement doses.

Receptor biology

MT1 receptors

  • Expressed in the SCN, pars tuberalis of the pituitary, retina, and cardiovascular tissue
  • Activation increases neuronal firing rate in the SCN during the biological night → increases sleep propensity
  • MT1 deletion in mice reduces REM sleep by ~37% and abolishes melatonin’s phase-shifting effects in vivo (PMID 23333399, PMID 16098087)
  • MT1 deletion in mice produces a melancholic depression-like phenotype — a circadian mood regulation pathway (PMID 25638817)

MT2 receptors

  • Expressed in the SCN, hippocampus, immune cells, and vascular smooth muscle
  • Activation suppresses forskolin-stimulated cAMP production in the SCN
  • MT2 deletion impairs NREM sleep consolidation in mice (PMID 23333399)
  • MT2-mediated vascular signaling produces vasodilatory effects via MT2/PI3K/AKT/eNOS pathway

Receptor-specific sleep effects

ReceptorPrimary functionSleep domain
MT1Increases nocturnal neuronal firing in SCN; promotes sleep propensityREM regulation
MT2Phase-shifting; suppresses cAMP in SCN; vasodilationNREM consolidation; phase advance

MT1 primarily regulates REM; MT2 primarily regulates NREM. This explains dose-dependent effects: physiological replacement doses preserve architecture; higher doses may alter REM/N3 in targeted populations (PMID 39400423).

Phase Response Curve (PRC)

The melatonin PRC is approximately 12 hours out of phase with the light PRC (PMID 1394610, PMID 9493716):

Administration timePhase effectPractical implication
MorningPhase delay (shifts clock later)Counterproductive for sleep onset
Afternoon / early eveningPhase advance (shifts clock earlier)Therapeutic for DSPD, jet lag
At / after DLMO onset (bedtime)Dead zone — minimal effectCommon timing error; 30-min timing falls here
NightVariable; minimal net effectNot used clinically

Optimal timing: 0.5 mg given 2–4 hours before DLMO (dim-light melatonin onset) produces maximal phase advance. For practical purposes, this is roughly 2–3 hours before target bedtime — not the commonly recommended 30 minutes (PMID 20410229, PMID 38888087).

DLMO is the personal biomarker for timing melatonin: it can be measured in saliva or inferred from dim-light sleep diaries. Most people have DLMO roughly 2–3 hours before habitual bedtime.

Key implications:

  • Taking melatonin at bedtime (common error) falls in the PRC dead zone — minimal phase-shifting benefit
  • Taking melatonin in the morning can cause phase delay — actively worsens sleep onset
  • For jet lag and DSPD: evening administration within the advance window shifts the clock earlier

See Circadian Biology for the SCN master clock and peripheral clock system.

Thermoregulation

Melatonin is a core component of the thermoregulatory sleep onset cascade:

  • Body temperature declines in the late evening as part of the circadian sleep preparation signal
  • Melatonin amplifies peripheral vasodilation (via MT2 receptors on vascular smooth muscle) → heat dissipation from core to periphery → drop in core body temperature
  • Core temperature decline facilitates sleep onset and NREM sleep maintenance
  • This is one reason dim-light environments improve melatonin’s efficacy — light suppresses both melatonin release and the natural temperature decline

Wearable relevance: Core body temperature is not measured by consumer wearables. Skin temperature at the wrist (Apple Watch) or finger (Oura) may show a small peripheral warming signal during melatonin-assisted sleep onset, but this has not been specifically validated.

HPA axis modulation

Direct adrenal effect ( primates)

MT1 receptors are expressed in the adrenal cortex. In primates, oral melatonin attenuates ACTH-stimulated cortisol production: 14.6 µg/dL (placebo) → 10.8 µg/dL (melatonin), p<0.01 (PMID 19301769). This is a direct suppressive effect on adrenal cortisol synthesis.

Central HPA axis (humans)

Melatonin per se has no substantially suppressing effect on HPA secretory activity in waking young men (PMID 16280028). Effects may be gated by sleep-related processes — the adrenal suppression is more apparent in sleep-disturbed populations.

Insomnia-specific correction

PR-melatonin corrects early-onset cortisol production in insomnia patients (PMID 20712869) — likely reflecting improved sleep continuity rather than a direct HPA suppressant effect.

Bottom line

Melatonin has a modest, context-dependent adrenal MT1 effect. At supplement doses in healthy adults, it is not a clinically significant HPA suppressant. In insomnia patients with elevated nocturnal cortisol, evening melatonin may normalize early cortisol spikes via improved sleep architecture.

Wearable relevance: Morning cortisol (cortisol awakening response / CAR) is not meaningfully suppressed by evening melatonin. Elevated nighttime HRV and lower resting HR during melatonin-assisted sleep may reflect improved circadian alignment, not direct HPA modulation.

Graph View

Backlinks